ArticleJournal of anesthesia2026
The effect of esketamine as adjuvant to ropivacaine for unilateral paravertebral block on postoperative pain and sensitization in adult patients undergoing video-assisted thoracoscopic surgery: a randomized clinical trial.
Article in Journal of anesthesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVideo-assisted thoracoscopic surgery (VATS) is accompanied by substantial acute postoperative pain, which may trigger sensitization and chronic postsurgical pain (CPSP). Despite multimodal analgesia, postoperative pain remains inadequately controlled. This study investigated whether low-dose esketamine as an adjuvant to paravertebral block (PVB) attenuates pain sensitization after VATS.
methods119 patients scheduled for elective VATS lobectomy were randomly allocated to two groups. Group K received PVB with 0.25% ropivacaine plus esketamine (0.5 mg/kg) after skin closure, whereas Group C received ropivacaine alone. Peripheral and central sensitization were assessed using mechanical pain thresholds on postoperative days (POD) 1 and 3. Postoperative pain was evaluated using the numerical rating scale (NRS) scores. CPSP and neuropathic components were assessed at 1 and 3 months postoperatively.
resultsGroup K showed lower rates of peripheral sensitization on POD 1 and POD 3 compared with group C (POD 1: 28.8% vs 58.3%, absolute risk reduction (ARR): 29.5%, RR 0.55, 95% CI 0.39-0.80, P = 0.001; POD 3: 25.4% vs 48.3%, ARR:22.9%, RR 0.63, 95% CI 0.44-0.88, P = 0.010). On POD 1, NRS scores in motion were lower in Group K (3.0 [2.0,4.0] vs 3.5 [3.0,5.0], P < 0.001). At 3 months, Group K showed a lower incidence of CPSP (20.4% vs 39.6%; ARR: 19.2%, RR 0.52, 95% CI 0.27-0.99, P = 0.039).
conclusionLow-dose esketamine as an adjuvant to PVB reduced postoperative pain, attenuated pain sensitization, and lowered the incidence of CPSP following VATS. This regimen may have potential clinical value but warrants further validation in larger studies.
Indexed as
Identifiers
41940968What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.